PRVA — what changed in the latest 10-Q
A section-by-section comparison of PRVA's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-06 vs the prior 10-Q · 2026-05-07
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +38 | −25 | ~28 | 37 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 0 |
| Legal proceedings | Text added/removed | +1 | −2 | 0 | 0 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +1 | −1 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-06
• Revenue was $632.6 million and $521.2 million for the three months ended June 30, 2026 and 2025, respectively, and $1.24 billion and $1.00 billion for the six months ended June 30, 2026 and 2025, respectively;
• Gross profit was $128.9 million and $112.8 million for the three months ended June 30, 2026 and 2025, respectively, and $254.5 million and $216.4 million for the six months ended June 30, 2026 and 2025, respectively;
• Operating income was $11.8 million and $3.3 million for the three months ended June 30, 2026 and 2025, respectively, and $19.2 million and $8.6 million for the six months ended June 30, 2026 and 2025, respectively; and
• Practice Collections were $970.0 million and $862.9 million for the three months ended June 30, 2026 and 2025, respectively, and $1.88 billion and $1.66 billion for the six months ended June 30, 2026 and 2025, respectively;
• Platform Contribution was $69.0 million and $57.5 million for the three months ended June 30, 2026 and 2025, respectively, and $136.0 million and $109.2 million for the six months ended June 30, 2026 and 2025, respectively; and
Text removed vs the prior filing · source: 10-Q · 2026-05-07
• Revenue was $603.8 million and $480.1 million for the three months ended March 31, 2026 and 2025, respectively;
• Gross profit was $125.6 million and $103.6 million for the three months ended March 31, 2026 and 2025, respectively;
• Operating income was $7.4 million and $5.2 million for the three months ended March 31, 2026 and 2025, respectively; and
• Practice Collections were $914.8 million and $798.6 million for the three months ended March 31, 2026 and 2025, respectively;
• Care Margin was $128.7 million and $105.3 million for the three months ended March 31, 2026 and 2025, respectively;
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-06
A description of our legal proceedings is included in and incorporated by reference to Note 10. “Commitments and Contingencies” of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Text removed vs the prior filing · source: 10-Q · 2026-05-07
We are currently involved in, and may in the future become involved in, legal proceedings, claims and investigations in the ordinary course of our business, including medical malpractice claims. These claims or proceedings can involve various types of parties, including governments, competitors, cus…
investigations may nonetheless impose a significant burden on management and employees and be costly to defend, with unfavorable preliminary or interim rulings.
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-06
On May 13, 2026, Parth Mehrotra, the Company’s Chief Executive Officer and a member of the Board, terminated a trading plan for the sale of securities intended to satisfy the affirmative defense conditions of Rule 10b5-1 of the Exchange Act, which he adopted on May 27, 2025 and was scheduled to end …
Text removed vs the prior filing · source: 10-Q · 2026-05-07
During the first quarter of 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice